ストックスクリーナーアプリを入手
42.59
4.25%
-1.89
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains Buy on Ultragenyx with $95 target By Investing.com - Investing.com Australia
Ultragenyx granted FDA priority review for gene therapy in rare brain disorder - MSN
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Reports Strong Growth Amid Challenges - TipRanks
Ultragenyx Pharmaceutical Inc. SEC 10-K Report - TradingView
Inside Ultragenyx's Latest Executive Compensation Package: New Hires Receive Strategic RSU Grants - StockTitan
Canaccord Genuity Group Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $136.00 - MarketBeat
H.C. Wainwright maintains Buy on Ultragenyx with $95 target - Investing.com India
Peregrine Capital Management LLC Acquires 29,684 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Trend Tracker for (RARE) - Stock Traders Daily
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year By Investing.com - Investing.com South Africa
Canaccord raises Ultragenyx target to $136, keeps Buy rating By Investing.com - Investing.com Australia
Ultragenyx stock gains on FDA priority review (RARE:NASDAQ) - Seeking Alpha
Canaccord raises Ultragenyx target to $136, keeps Buy rating - Investing.com India
Ultragenyx Announces FDA Acceptance and Priority Review of - GlobeNewswire
Ultragenyx's Revolutionary Gene Therapy for Fatal Childhood Disease Advances: FDA Fast-Tracks Review - StockTitan
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from HC Wainwright - MarketBeat
Ultragenyx's SWOT analysis: rare disease biotech stock eyes pivotal year - Investing.com India
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating - TipRanks
Ultragenyx stock holds Buy rating, $140 target from Truist - MSN
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Goldman Sachs maintains buy on Ultragenyx, target at $78 - MSN
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - MSN
Cantor Fitzgerald maintains $118 target on Ultragenyx stock - MSN
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views - Benzinga
Cantor Fitzgerald maintains $118 target on Ultragenyx stock By Investing.com - Investing.com Nigeria
Goldman Sachs maintains buy on Ultragenyx, target at $78 By Investing.com - Investing.com South Africa
Ultragenyx stock holds Buy rating, $140 target from Truist By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highl - GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx: Q4 Earnings Snapshot - The Herald Review
Ultragenyx Pharmaceutical Reports Strong 2024 Growth - TipRanks
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
2 Anti-Kickback Developments Hold Lessons For Biopharma - Law360
ULTRAGENYX PHARMACEUTICAL Earnings Results: $RARE Reports Quarterly Earnings - Nasdaq
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Nasdaq
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):